Comparison
GHRP-6 vs. TB-500
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Growth
Healing
CAS no.
87616-84-0
no data
Molecular weight
873.02 g/mol
888 g/mol
Half-life
0.4 h
no data
Sequence
His-D-Trp-Ala-Trp-D-Phe-Lys-NH2Ac-LKKTETQMechanism of action
GHRP-6
GHRP-6 is a high-affinity agonist of the growth-hormone secretagogue receptor 1a (GHSR-1a) — the same receptor later shown to bind the endogenous hormone ghrelin. The identification of GHRP-6 as a pharmacological anchor led to cloning of GHSR in 1996 and the discovery of ghrelin itself in 1999. GHRP-6 stimulates pituitary GH secretion via a pathway independent of GHRH and can be combined synergistically with GHRH. Via GHSR in the hypothalamus it additionally activates NPY/AgRP neurons, producing an orexigenic (appetite-stimulating) effect in animal models.
TB-500
Synthetic fragment of the endogenous protein Thymosin Beta-4. In preclinical models, an influence on cell migration, actin sequestration and neovascularisation has been described. Robust human pharmacokinetic data are not publicly available.
Evidence base
Highest evidence
Human trial
Animal model
Studies
4
3
of which in humans
2
0
Effects recorded
4
4
Open conflicts
1
1
Documented adverse events
2
2